• Guidance on Exceptions to the NIH Single IRB Policy  
  (NOT-OD-18-003)  
  National Institutes of Health

  (NOT-OD-18-004)  
  National Institutes of Health

• Findings of Research Misconduct  
  (NOT-HL-17-359)  
  National Institutes of Health

• Notice of a Pre-Application Webinar for RFA-CA-17-050, Pediatric Immunotherapy Discovery and Development Network (PI-DDN) (U54)  
  (NOT-CA-17-096)  
  National Cancer Institute

• Notice of a Pre-Application Webinar for RFA-CA-17-051, Pediatric Immunotherapy Discovery and Development Network (PI-DDN) (U01)  
  (NOT-CA-17-097)  
  National Cancer Institute

• Notice of Correction to PAR-17-496, Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)  
  (NOT-CA-18-001)  
  National Cancer Institute

• Notice of Correction to Scientific Merit Review Dates in PAR-17-203, Inter-organelle Communication in Cancer (R01)  
  (NOT-CA-18-003)  
  National Cancer Institute

• Notice of Correction to Scientific Merit Review Dates in PAR-17-204, Inter-organelle Communication in Cancer (R21)  
  (NOT-CA-18-004)  
  National Cancer Institute

• Notice of a Pre-Application Webinar for the Immuno-Oncology Translation Network (IOTN): RFA-CA-17-045 (U01), RFA-CA-17-046 (U01), RFA-CA-17-047 (U24), and RFA-17-048 (U24)  
  (NOT-CA-18-005)  
  National Cancer Institute

• Notice of NIH Institutes and CDC Participation in PA-18-314 “Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp)”  
  (NOT-CA-18-006)  
  National Cancer Institute

• Reminder: FORMS-E Grant Application Forms and Instructions Must be Used for Due Dates On or After January 25, 2018  
  (NOT-OD-18-009)  
  National Institutes of Health

• Notice of a Pre-Application Webinar for RFA-CA-17-032, Minority Patient-Derived Xenograft (PDX) Development and Trial Centers (M-PDTCs) U54)  
  (NOT-CA-18-013)  
  National Cancer Institute

• Statement on Article Publication Resulting from NIH Funded Research  
  (NOT-OD-18-011)  
  National Institutes of Health

• Request for Information (RFI): Information Resources on Lifestyle and Behavioral Factors Contributing to the Effectiveness of Cancer Therapies  
  (NOT-CA-18-002)  
  National Cancer Institute

• Notice of Pre-application Webinar for RFA-CA-17-056 Limited Competition: NCI National Clinical Trials Network- Network Group Operations Centers (U10)  
  (NOT-CA-18-007)  
  National Cancer Institute

• Notice of Pre-application Webinar for RFA-CA-17-059 National Clinical Trials Network – Network Lead Academic Participating Sites (UG1)  
  (NOT-OD-18-010)  
  National Cancer Institute

• Notice of Pre-application Webinar for RFA-CA-17-033 Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20)  
  (NOT-CA-18-014)  
  National Cancer Institute

• Notice of Pre-application Webinar for Human Tumor Atlas Network (HTAN) Initiative (RFA-CA-17-043, RFA-CA-17-035), and RFA-CA-17-036)  
  (NOT-CA-18-015)  
  National Cancer Institute
REQUEST FOR APPLICATIONS

• **TITLE:** Minority-Patient Derived Xenograft (PDX) Development and Trial Center (PDTC) Network (U54)  
  (RFA-CA-17-032)  
  **SPONSOR:** National Cancer Institute  
  **Synopsis:** This funding opportunity announcement (FOA) solicits applications for Minority PDX (minority patient-derived xenografts) Development and Trial Centers (M-PDTCs). The M-PDTCs will join the PDTC Research Network (PDXNet) and be focused upon development and pre-clinical testing of models derived from racial/ethnic minority populations. The PDXNet is a National Cancer Institute (NCI) program established to coordinate collaborative, large-scale model development and pre-clinical testing of targeted therapeutic agents to advance the vision of cancer precision medicine.  
  **Application Receipt Date(s):** January 18, 2018

• **TITLE:** Feasibility and Planning Studies for Development of Specialized Programs for Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20)  
  (RFA-CA-17-033)  
  **SPONSOR:** National Cancer Institute  
  **Synopsis:** This Funding Opportunity Announcement (FOA) invites applications for development of translational research programs that are focused upon investigating cancer health disparities. The P20 grants will support feasibility and planning activities to build cancer health disparities research programs. It is the expectation that the research programs developed by the P20 awards should be competitive with other applications for a full Specialized Programs of Research Excellence (SPORE), addressing cancer health disparities as a cross-cutting research theme.  
  **Receipt Date(s):** January 18, 2018

• **TITLE:** Immuno-Oncology Translational Network (IOTN): Cancer Immunotherapy Research Projects (U01)  
  (RFA-CA-17-045)  
  **SPONSOR:** National Cancer Institute  
  **Synopsis:** This funding opportunity announcement (FOA) will establish an Immuno-Oncology Translation Network (IOTN) with the overall goal of accelerating research advances through collaborative team science approaches to improve immunotherapy outcomes for diverse cancers that are either resistant or develop resistance to immunotherapies. Specifically, this strategy is expected to discover new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur.  
  **Receipt Date(s):** January 16, 2018

• **TITLE:** Immuno-Oncology Translation Network (IOTN): Cancer Immunoprevention Research Projects (U01)  
  (RFA-CA-17-046)  
  **SPONSOR:** National Cancer Institute  
  **Synopsis:** This funding opportunity announcement (FOA) will establish an Immuno-Oncology Translation Network (IOTN) with the overall goal of accelerating research advances through collaborative team science approaches to improve immunotherapy outcomes for diverse cancers that are either resistant or develop resistance to current immunotherapies. Specifically, this strategy is expected to discover new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur.  
  **Receipt Date(s):** January 16, 2018

• **TITLE:** Immuno-Oncology Translational Network (IOTN): Data Management and Resource- Sharing Center (DMRC) (U24)  
  (RFA-CA-17-047)  
  **SPONSOR:** National Cancer Institute  
  **Synopsis:** This funding opportunity announcement (FOA) will establish an Immuno-Oncology Translation Network (IOTN) with the overall goal of accelerating research advances through collaborative team science approaches to improve immunotherapy outcomes for diverse cancers that are either resistant or develop resistance to...
immunotherapies. Specifically, this strategy is expected to discover new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur.

Receipt Date(s): January 16, 2018

**TITLE:** Immuno-Oncology Translation Network (IOTN): Cellular Immunotherapy Data Resource (CIDR) (U24)
**(RFA-CA-17-048)**
**SPONSOR:** National Cancer Institute

**Synopsis:** The purpose of this FOA is to establish a Data Resource associated with clinical trials in cellular immunotherapy as a component of the Immuno-Oncology Translation Network (IOTN). Projects proposed should focus on establishing an efficient infrastructure to collect and analyze outcomes data of cellular immunotherapy trials (NCI-sponsored, investigator-initiated, or pharmaceutical company-sponsored) or with an FDA-approved agent and facilitating analysis of the observational data for the design of pre-clinical research in the Cancer Immunotherapy Consortium (CIC) and elsewhere, as well as inform design of future trials.

Receipt Date(s): January 16, 2018

**TITLE:** Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS): Coordinating Center (U24)
**(RFA-CA-17-039)**
**SPONSOR:** National Cancer Institute

**Synopsis:** The purpose of this FOA is to promote research in colorectal cancer (CRC) screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based Approaches.

Receipt Date(s): January 18, 2018

**TITLE:** Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01) – (Clinical Trials Not Allowed)
**(RFA-HL-18-026)**
**SPONSOR:** National Cancer Institute

**Synopsis:** This Funding Opportunity Announcement (FOA) invites applications to enhance the pool of highly trained investigators from diverse backgrounds underrepresented in research. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations.

Receipt Date(s): February 20, 2018

**TITLE:** Human Tumor Atlases (HTA) Research Centers (U2C)
**(RFA-CA-17-034)**
**SPONSOR:** National Cancer Institute

**Synopsis:** This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research that results in a comprehensive view of the dynamic multidimensional tumor ecosystem. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Generation of Human Tumor Atlases.

Receipt Date(s): January 18, 2018

**TITLE:** Human Tumor Atlases (HTA) Precancer Atlas Research Centers (U2C)
**(RFA-CA-17-035)**
**SPONSOR:** National Cancer Institute

**Synopsis:** This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research that results in a comprehensive view of the dynamic multidimensional tumor ecosystem. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Generation of Human Tumor Atlases.

Receipt Date(s): January 18, 2018

**TITLE:** Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS) (UG3/UH3)
**(RFA-CA-17-038)**
**SPONSOR:** National Cancer Institute

**Synopsis:** This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. This purpose of this FOA is to promote research in colorectal cancer (CRC) screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority...
by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based approaches.
Receipt Date(s): January 18, 2018

• **TITLE:** Research Centers for Improving Management of Symptoms Across Cancer Treatments (IMPACT) (RFA-CA-17-042)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative established to accelerate cancer research. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): the Implementation of Integrated and Evidenced-based Symptom Management Throughout the Cancer Trajectory. The purpose of this specific FOA is to promote research on the implementation and evaluation of integrated symptom monitoring and management systems for use in cancer care delivery through a Research Consortium. This research will provide new insights and valuable evidence that can be used to guide efforts on a nation-wide basis to improve symptom control for cancer patients during treatment and survivorship.
  Receipt Date(s): January 17, 2018

• **TITLE:** Coordinating Center for Improving Management of Symptoms Across Cancer Treatments (IMPACT) (U24) (RFA-CA-17-043)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative established to accelerate cancer research. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): the Implementation of Integrated and Evidenced-based Symptom Management Throughout the Cancer Trajectory. The purpose of this specific FOA is to promote research on the implementation and evaluation of comprehensive symptom management systems for use in cancer care delivery through a Research Consortium. This research will provide new insights and valuable evidence that can be used to guide efforts on a nation-wide basis to improve symptom control for cancer patients during treatment and survivorship.
  Receipt Date(s): January 17, 2018

• **TITLE:** Mechanisms of Cancer Drug Resistance and Sensitivity: Coordinating Center (U24) (RFA-CA-17-044)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to create a U24 Coordinating Center that will integrate and facilitate trans-disciplinary research across the Drug Resistance and Sensitivity Centers (DRSCs) U54s established under RFA-CA-17-009; and to the extent possible coordinate its activities with other Cancer Moonshot coordinating centers and NCI programs. The DRSC U54s will conduct basic and preclinical research focused on investigating the mechanisms of tumor resistance (intrinsic or acquired) and sensitivity and on developing new therapeutic strategies that either combat tumor resistance or exploit its sensitivity. These strategies will explore genetic and other molecular characteristics of the cancer underlying sensitivity/resistance to anticancer treatments.
  Receipt Date(s): January 5, 2018

**PROGRAM ANNOUNCEMENTS**

• **TITLE:** Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp) (PAR-18-314)
  **SPONSOR:** National Cancer Institute
  Center for Advancing Translational Sciences
  National Center for Emerging and Zoonotic Infectious Diseases
  National Human Genome Research Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Environmental Health Sciences
  National Institute of Mental Health
  National Institute of Neurological Disorders and Stroke
  National Institute for Occupational Safety and Health
  Application Receipt/Submission Date(s): December 18, 2017

• **TITLE:** Testing Interventions for Health-Enhancing Physical Activity (R01 – Clinical Trial Optional) (PAR-17-306)
SPONSOR: Office of Disease Prevention
National Center for Complementary and Integrative Health
National Cancer Institute
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
National Center on Drug Abuse
National Institute on Minority Health and Health Disparities
Application Receipt/Submission Date(s): Multiple dates, see announcement

• TITLE: Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3- Clinical Trials Not Allowed)  
(PAR-18-310)
SPONSOR: National Cancer Institute
Application Receipt/Submission Date(s): Multiple dates, see announcement

• TITLE: Specialized Programs of Research Excellence (SPOREs) in Human Cancers for years 2018, 2019 and 2020 (P50)  
(PAR-18-313)
SPONSOR: National Cancer Institute
National Institute of Dental and Craniofacial Research
Application Receipt/Submission Date(s): Standard dates apply

• TITLE: Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 – Clinical Trials Not Allowed)  
(PAR-18-317)
SPONSOR: National Cancer Institute
Application Receipt/Submission Date(s): Multiple dates, see announcement

• TITLE: National Cancer Institute Program Project Applications (P01)  
(PAR-16-457)
SPONSOR: National Cancer Institute
United States Department of Health and Human Services (HHS)
Application Receipt/Submission Date(s): January 7, 2018

• TITLE: Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Optional)  
(PA-18-001)
SPONSOR: National Cancer Institute
National Center for Complementary and Integrative Health
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Drug Abuse
Application Receipt Date(s): Multiple dates, see announcement

• TITLE: Examination of Survivorship Care Planning Efficacy and Impact (R01 Clinical Trial Optional)  
(PA-18-002)
SPONSOR: National Cancer Institute
Application Receipt/Submission Date(s): Multiple dates, see announcement.

• TITLE: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01 Clinical Trial Optional)  
(PA-18-003)
SPONSOR: National Cancer Institute
National Heart, Lung, and Blood Institute
Application Receipt Date(s): Standard dates apply

• TITLE: Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R01 Clinical Trial Optional)  
(PA-18-004)
SPONSOR: National Cancer Institute
Application Receipt Date(s): Standard dates apply

• TITLE: Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (R01 Clinical Trial Optional)  
(PA-18-005)
SPONSOR: National Cancer Institute
National Institute on Aging
Application Receipt Date(s): Standard dates apply

• TITLE: Diet and Physical Activity Assessment Methodology (R01 Clinical Trial Optional)  
(PA-18-010)
SPONSOR: National Institute of Diabetes and Digestive and Kidney Diseases
• TITLE: Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R21 Clinical Trial Optional) (PA-18-014)
SPONSOR: National Cancer Institute
Application Receipt Date(s): Standard dates apply

• TITLE: Potential Effects of Metformin on Aging and Age-Related Conditions: Small-Scale Clinical Studies and Secondary Analysis of Controlled Clinical Studies (R01 Clinical Trial Optional) (PA-18-025)
SPONSOR: National Cancer Institute
National Institute on Aging
Application Receipt Date(s): Standard dates apply

• TITLE: Nutrigenetics and Nutrigenomics Approaches for Nutrition Research (R01 Clinical Trial Optional) (PA-18-034)
SPONSOR: National Institute of Diabetes and Digestive and Kidney Diseases
National Center for Complementary and Integrative Health
National Cancer Institute
Office of Dietary Supplements
Application Receipt Date(s): Standard dates apply

• TITLE: Addressing Health Disparities through Effective Interventions Among Immigrant Populations (R01 Clinical Trial Optional) (PA-18-284)
SPONSOR: National Institute on Minority Health and Health Disparities
National Cancer Institute
National Institute on Alcohol Abuse and Alcoholism
National Institute on Drug Abuse
National Institute of Environmental Health Sciences
Application Receipt Date(s): Standard dates apply

• TITLE: Revision Applications for Validation of Mobile/Wireless Health Tools for Measurement and Intervention (R01) Clinical Trial Optional (PA-18-339)
SPONSOR: Office of Behavioral and Social Science Research
National Cancer Institute
National Institute of Biomedical Imaging and Bioengineering
National Institute on Deafness and Other Communication Disorders
Application Receipt Date(s): Standard dates apply

• TITLE: Dissemination and Implementation Research in Health (R01 Clinical Trial Optional) (PAR-18-007)
SPONSOR: National Cancer Institute
National Center for Complementary and Integrative Health
National Human Genome Research Institute
National Heart, Lung, and Blood Institute
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
National Institute of Allergy and Infectious Diseases
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Drug Abuse
National Institute on Deafness and Other Communication Disorders
National Institute of Dental and Craniofacial Research
National Institute of Environmental Health Sciences
National Institute of Mental Health
National Institute on Minority Health and Health Disparities
National Institute of Neurological Disorders and Stroke
National Institute of Nursing Research
Office of Behavioral and Social Science Research
Office of Disease Prevention
Application Receipt Date(s): Standard dates apply

- **TITLE:** National Cancer Institute Program Project Applications (P01 Clinical Trial Optional)  
  (PAR-18-290)  
  **SPONSOR:** National Cancer Institute  
  Application Receipt Date(s): Standard dates apply

- **TITLE:** NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 - Clinical Trials Required)  
  (PAR-18-336)  
  **SPONSOR:** National Cancer Institute  
  Application Receipt Date(s): Standard dates apply

- **TITLE:** NCI Research Specialist (Core-based Scientist) Award (R50)  
  (PAR-18-342)  
  **SPONSOR:** National Cancer Institute  
  Application Receipt Date(s): Standard dates apply

**OTHER FUNDING OPPORTUNITIES**  
(Sponsors in bold are NIH Peer Reviewed Organizations)

- **TITLE:** Kidney Cancer Research Program Translational Research Partnership Award  
  [http://cdmrp.army.mil/funding/kcr](http://cdmrp.army.mil/funding/kcr)  
  **SPONSOR:** United States Department of Defense

- **TITLE:** Scientific Scholar Award  
  **SPONSOR:** Marsha Rivkin Center for Ovarian Cancer Research

- **TITLE:** Medical Research Grants  
  [http://www.earlier.org/prospective](http://www.earlier.org/prospective)  
  **SPONSOR:** Friends for an Earlier Breast Cancer Test

- **TITLE:** Collaborative Pediatric Cancer Research Awards Program  
  [https://rallyfoundation.org/research/become-a-rally-funded-researcher/](https://rallyfoundation.org/research/become-a-rally-funded-researcher/)  
  **SPONSOR:** Rally Foundation for Childhood Cancer Research

- **TITLE:** AICR Research Grant Program: Investigator-Initiated Grants (IIGs)  
  [http://www.aicr.org/research/grant/research_funded_grant_programs.html](http://www.aicr.org/research/grant/research_funded_grant_programs.html)  
  **SPONSOR:** American Institute for Cancer Research (AICR)

- **TITLE:** Research Grants  
  [http://terribrodeurbreastcancerfoundation.org/granting-process/](http://terribrodeurbreastcancerfoundation.org/granting-process/)  
  **SPONSOR:** Terri Brodeur Breast Cancer Foundation (TBBCF)

- **TITLE:** Jeffress Trust Awards Program in Interdisciplinary Research  
  [https://hria.org/tmf/jeffress/](https://hria.org/tmf/jeffress/)  
  **SPONSOR:** The Jeffress Memorial Trust